Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

Beam Therapeutics is focused on developing precision genetic medicines using base editing technologies.

Beam Therapeutics

Beam Therapeutics | 66,012 followers on LinkedIn. Our vision is to provide life-long cures for patients suffering from serious diseases. | Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.

Executive Assistant

Jocelyn Mortero

Licensed Patent Attorney with twenty years of experience in the life sciences

William Schmidt

Nada Martini

Sr. Director, EHS at Beam Therapeutics

Mandy Stone

Curious how base editing works? Check out our animation and learn how the #BeamTeam is tackling diseases one letter at a time! #DaretoBeam

Today, the #BeamTeam ’s John Evans joined the #ASAPBioPharma Conference as the Keynote and shared Beam’s approach to gene editing and discussed how strategic partnerships are critical to advancing and expanding patient options to support them living their best lives. Thank you, Association of Strategic Alliance Professionals for hosting the #BeamTeam ! #DaretoBeam

Today, Beam Therapeutics announced the acceptance of multiple oral and poster presentations, including the first clinical data from a Beam program, at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego. Full press release here: https://lnkd.in/eBy7_ekU #DaretoBeam

Today, Beam Therapeutics reported third quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises. Full details here: https://lnkd.in/eZcxiw-K Reminder: Beam will host a conference call today, November 5, 2024, at 8:30 a.m. ET. To join the conference call, visit the link in the press release #DaretoBeam

The #BeamTeam recently participated in The Leukemia & Lymphoma Society 's Light The Night in Boston and North Carolina. Thank you to everyone who walked in support of, to celebrate, honor, and remember those touched by blood cancers. #LightTheNight #DaretoBeam

Beam will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here: https://lnkd.in/eruR6iPf and under "Events & Presentations" in the Investors section of Beam's website at www.beamtx.com .

Our Clinical Operations Team is growing and looking for an experienced Senior Clinical Trial Manager! This role must fully understand and lead the cross-functional team through all day-to-day activities within the clinical trial life cycle. These day-to-day activities include managing all trial start-up, conduct and close-out activities to both industry and corporate standards within ICH/GCP Guidelines. Learn more here #DaretoBeam : https://lnkd.in/e29w5nAx

Beam is looking for highly energetic and curious Co-ops across multiple departments to join the #BeamTeam ! Check out our Co-op opportunities here: https://lnkd.in/eduTfpdQ #DaretoBeam

Recently, the #BeamTeam celebrated the end of summer and start of fall in NC and MA! Thank you to the entire Beam Team for the hard work and dedication to our vision and each other! #TallShipBoston

Throughout September, the #BeamTeam in MA and NC participated in #Alpha1RidingforaReason to raise awareness of Alpha 1 antitrypsin deficiency and its impact on affected families. #Alpha1

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			18K -	24K 33.33%	51.84M 215,916.67%	60.92M 17.51%	377.71M 520.01%
cost of revenue							20.01M -
gross profit			18K -	24K 33.33%	51.84M 215,916.67%	60.92M 17.51%	357.70M 487.16%
selling and marketing expenses							-20.01M -
general and administrative expenses	2.02M -	11.87M 487.23%	20.55M 73.18%	29.61M 44.04%	57.22M 93.28%	87.81M 53.45%	116.81M 33.04%
selling general and administrative expenses	2.02M -	11.87M 487.23%	20.55M 73.18%	29.61M 44.04%	57.22M 93.28%	87.81M 53.45%	96.80M 10.25%
research and development expenses	5.86M -	33.87M 478.14%	54.62M 61.25%	103.18M 88.91%	387.09M 275.16%	311.59M 19.50%	437.38M 40.37%
other expenses	378K -	-10.04M 2,756.08%	-71K 99.29%
cost and expenses	7.88M -	45.74M 480.47%	75.17M 64.34%	132.78M 76.64%	444.31M 234.61%	399.40M 10.11%	554.19M 38.76%
operating expenses	7.88M -	45.74M 480.47%	75.17M 64.34%	132.78M 76.64%	444.31M 234.61%	399.40M 10.11%	534.18M 33.75%
interest expense			187K -	1.57M 738.50%	-9K 100.57%	15.30M 170,066.67%	46.68M 205.13%
ebitda	-7.37M -	16.16M 319.27%	-69.24M 528.49%	-64.63M 6.66%	-414.30M 541.08%	-401.48M 3.09%	-156.47M 61.03%
operating income	-7.88M -	-45.74M 480.47%	-75.15M 64.30%	-132.76M 76.65%	-392.46M 195.62%	-338.48M 13.76%	-176.49M 47.86%
depreciation and amortization	11K -	650K 5,809.09%	5.92M 810.46%	68.14M 1,051.32%	-21.84M 132.05%	-63.00M 188.53%	20.01M 131.76%
total other income expenses net	-122K -	-71.29M 58,333.61%	-3.17M 95.55%	-61.83M 1,849.31%	21.83M 135.30%	78.30M 258.73%	45.32M 42.12%
income before tax	-8.00M -	-116.74M 1,358.86%	-78.33M 32.90%	-194.59M 148.44%	-370.64M 90.47%	-260.18M 29.80%	-131.16M 49.59%
income tax expense	500K -	-71.00M 14,299.40%	116K 100.16%	61.83M 53,203.45%	-29.28M 147.35%	3.41M 111.65%	1.37M 59.94%
net income	-8.00M -	-115.26M 1,340.35%	-78.44M 31.94%	-256.42M 226.90%	-341.36M 33.12%	-263.59M 22.78%	-132.53M 49.72%
weighted average shs out	12.95M -	35.14M 171.27%	45.32M 28.99%	46.73M 3.11%	64.23M 37.43%	70.02M 9.01%	77.15M 10.19%
weighted average shs out dil	12.95M -	35.14M 171.27%	45.32M 28.99%	46.73M 3.11%	64.23M 37.43%	70.02M 9.01%	77.15M 10.19%
eps	-0.62 -	-3.28 429.03%	-1.73 47.26%	-5.49 217.34%	-5.31 3.28%	-3.76 29.19%	-1.72 54.26%
epsdiluted	-0.62 -	-3.28 429.03%	-1.73 47.26%	-5.49 217.34%	-5.31 3.28%	-3.76 29.19%	-1.72 54.26%

COM:BEAMTX

Beam Therapeutics

Last Close

23.58

22/11 21:00

Market Cap

1.97B

Beta: -

Volume Today

1.16M

Avg: -

Preview